Agilent Technologies (A) Downgraded by ValuEngine
ValuEngine downgraded shares of Agilent Technologies (NYSE:A) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning.
A number of other equities analysts also recently weighed in on the stock. JPMorgan Chase & Co. upped their price target on shares of Agilent Technologies from $75.00 to $80.00 and gave the stock an overweight rating in a research note on Thursday, February 15th. Robert W. Baird reaffirmed a buy rating and issued a $76.00 price target on shares of Agilent Technologies in a research note on Thursday, January 18th. Barclays reaffirmed a buy rating and issued a $74.00 price target on shares of Agilent Technologies in a research note on Monday, January 8th. Evercore ISI began coverage on shares of Agilent Technologies in a research note on Wednesday, January 3rd. They issued an outperform rating and a $75.00 price target on the stock. Finally, Cowen reaffirmed a hold rating and issued a $70.00 price target on shares of Agilent Technologies in a research note on Wednesday, November 22nd. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $70.98.
Shares of Agilent Technologies (NYSE:A) opened at $71.13 on Wednesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.78 and a current ratio of 3.23. Agilent Technologies has a one year low of $51.48 and a one year high of $75.00. The stock has a market cap of $23,360.00, a price-to-earnings ratio of 31.75, a price-to-earnings-growth ratio of 2.34 and a beta of 1.30.
In other Agilent Technologies news, CEO Michael R. Mcmullen sold 21,850 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,638,750.00. Following the completion of the sale, the chief executive officer now directly owns 324,687 shares in the company, valued at $24,351,525. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark Doak sold 15,567 shares of the company’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $68.00, for a total transaction of $1,058,556.00. Following the sale, the insider now owns 71,104 shares of the company’s stock, valued at $4,835,072. The disclosure for this sale can be found here. Insiders sold 102,970 shares of company stock valued at $7,340,641 over the last quarter.
A number of hedge funds have recently added to or reduced their stakes in A. Dupont Capital Management Corp bought a new stake in Agilent Technologies during the third quarter valued at about $101,000. Front Row Advisors LLC bought a new stake in shares of Agilent Technologies in the fourth quarter valued at about $106,000. Compagnie Lombard Odier SCmA bought a new stake in shares of Agilent Technologies in the fourth quarter valued at about $126,000. AMG National Trust Bank bought a new stake in shares of Agilent Technologies in the fourth quarter valued at about $201,000. Finally, Premia Global Advisors LLC bought a new stake in shares of Agilent Technologies in the fourth quarter valued at about $204,000.
ILLEGAL ACTIVITY NOTICE: “Agilent Technologies (A) Downgraded by ValuEngine” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2018/03/11/agilent-technologies-a-downgraded-by-valuengine.html.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.